CareDx (CDNA) has announced its anticipated third-quarter revenue, projecting figures between $82 million and $83 million. This represents an approximate 23% growth compared to the same quarter last year. Revenue from testing services is expected to fall between $60 million and $61 million, marking an approximate 26% increase year-over-year. The company concluded the quarter with around $240 million in cash, cash equivalents, and marketable securities, maintaining a debt-free status.
"Our performance remains robust as we approach the fourth quarter," stated John Hanna, President and CEO of CareDx.
